Estamos no ar no ! Saiba mais

Immix Biopharma

IMMX

Valor de mercado US$ 662 mi

7,98 USD

-0,70

8,06%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

7,99

+0,01

0,13%

1 dia

-8,06%

5 dias

-15,29%

1 mês

-33,05%

3 meses

-20,68%

6 meses

-19,88%

No acumulado do ano

46,96%

1 ano

195,56%

5 anos

117,44%

10 anos

117,44%

Sobre: Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Funcionários: 21

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 5,6%

Neutro 94,4%

Negativo 0%

Neutro

GlobeNewsWire

há 11 dias

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

Positivo

MarketBeat

há 12 dias

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

Immix Biopharma NASDAQ: IMMX reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch strategy.

Neutro

GlobeNewsWire

há 16 dias

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share.

Neutro

Seeking Alpha

há 17 dias

Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript

Neutro

GlobeNewsWire

há 17 dias

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions.

Neutro

GlobeNewsWire

há 17 dias

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis

– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –

$Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis$